中文 | English
Return
Total: 6 , 1/1
Show Home Prev Next End page: GO
Author:(Chengxu CUI)

1.Chemotherapy and comparison of agents for advanced duodenal carcinoma

Junbao LIU ; Chengxu CUI ; Jinwan WANG ; Yurong ZHANG ; Nan WANG ; Wei LIU ; Chunhui GAO ; Shuping SHI ; Haijian TANG ; Zhujun SHAO ; Tingting YANG

Chinese Journal of Clinical Oncology 2014;(5):319-323

2.Chemotherapy for metastatic colorectal cancer after failure of treatment with irinotecan and oxaliplatin

Junbao LIU ; Yurong ZHANG ; Tao QU ; Shuping SHI ; Zhujun SHAO ; Tingting YANG ; Haijian TANG ; Nan WANG ; Wei LIU ; Chunhui GAO ; Chengxu CUI

Chinese Journal of Clinical Oncology 2013;(23):1464-1467

3.Inhibitory effect of mucopolysaccharide polysulfate cream on hypertrophic scar formation in a rabbit ear model and its mechanisms of action

Yan JING ; Wenmin FEI ; Chengxu LI ; Yong CUI

Chinese Journal of Dermatology 2022;55(8):720-726

4.FOLFOX/XELOX plus cetuximab administered weekly versus biweekly as a first-line treatment for patients with KRAS/RAS wild-type metastatic colorectal cancer: a retro-spective study

Yue YU ; Wen ZHANG ; Yongkun SUN ; Lin YANG ; Chengxu CUI ; Yixin ZENG ; Aiping ZHOU

Chinese Journal of Clinical Oncology 2018;45(23):1210-1214

5. Biweekly paclitaxel and platinum chemotherapy followed by surgery for esophageal squamous cell carcinoma

Liangze ZHANG ; Weiwei LI ; Chengxu CUI ; Hongtu ZHANG ; Yan SONG ; Yousheng MAO ; Jing HUANG

Chinese Journal of Oncology 2017;39(3):216-219

6.Deficiency of two-pore segment channel 2 contributes to systemic lupus erythematosus via regulation of apoptosis and cell cycle.

Keke LI ; Jingkai XU ; Ke XUE ; Ruixing YU ; Chengxu LI ; Wenmin FEI ; Xiaoli NING ; Yang HAN ; Ziyi WANG ; Jun SHU ; Yong CUI

Chinese Medical Journal 2022;135(4):447-455

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 6 , 1/1 Show Home Prev Next End page: GO